Novanta INC

Novanta Inc. has finalized its acquisition of Riverpoint Medical for approximately $1.2 billion, significantly expanding its medical consumables business and recurring revenue.

Novanta Inc. announced its definitive agreement to acquire Riverpoint Medical for $1.2 billion in cash plus a $250 million milestone payment, aiming to accelerate its strategic shift towards recurring revenue in the minimally invasive surgery sector.

Novanta Inc. shareholders re-elected all nine director nominees and approved executive compensation and auditor appointments at the 2026 Annual Meeting.

Novanta Inc. has amended its credit agreement to establish a $200 million delayed draw term loan facility maturing in 2030.

Novanta Inc. announced its first quarter 2026 financial results, showcasing a 10% increase in GAAP revenue to $257.7 million and a 14% rise in Adjusted EBITDA to $57 million.

Novanta Inc. reported strong fourth-quarter 2025 financial results, exceeding revenue expectations with 9% growth and outlining plans for continued momentum and strategic acquisitions in 2026.

Novanta Inc. reported a 10.4% increase in revenue for the first quarter of 2026, reaching $257.7 million, driven by growth in both its segments, though earnings per share saw a decline.

Novanta Inc. reported a significant decline in net income and earnings per share for the third quarter and first nine months of 2025, despite modest revenue growth, driven by increased operating expenses and restructuring costs.

Novanta Inc. reports a 2.2% revenue increase for Q2 2025, driven by acquisitions and Automation Enabling Technologies, but operating income and EPS declined due to higher restructuring and acquisition costs.

Novanta Inc. saw a slight increase in revenue and a significant jump in operating income for the first quarter of 2025, driven by growth in the Automation Enabling Technologies segment and a gain on the sale of a facility.

Novanta Inc.'s Q3 2024 results show revenue growth driven by acquisition, but profitability is impacted by integration costs and market softness.

Novanta Inc.'s Q2 2024 results show revenue growth driven by acquisition, but operating income declined due to increased expenses and weaker industrial demand.

Novanta Inc. reported a 3.3% revenue increase to $980.6 million in 2025, but operating income and EPS declined significantly due to increased expenses and restructuring costs, while bolstering liquidity with a $613.1 million equity unit issuance.

Novanta Inc. announces a 7.7% increase in revenue for fiscal year 2024, primarily driven by the acquisition of Motion Solutions and growth in the Medical Solutions segment, while facing challenges in the advanced industrial market.

Novanta Inc. announces its financial results for the year ended December 31, 2023, highlighting revenue growth and strategic acquisitions.

Novanta Inc. CEO Matthijs Glastra reported the sale of company stock totaling over $1.6 million, executed under a pre-established Rule 10b5-1 trading plan.

Novanta Inc. CEO Matthijs Glastra sold a significant number of company shares through a pre-arranged Rule 10b5-1 trading plan.

Novanta Inc. CEO Matthijs Glastra sold 6,500 shares of common stock via a pre-established Rule 10b5-1 trading plan.

Novanta Inc.'s Chief Financial Officer, Robert Buckley, executed a pre-arranged Rule 10b5-1 trading plan, exercising stock options and selling 9,957 shares of common stock.

Novanta Inc.'s CEO, Matthijs Glastra, sold 6,500 shares of common stock totaling approximately $849,241 through a pre-established Rule 10b5-1 trading plan.

Novanta Inc.'s Co-Chief Operating Officer, Charles Guy Ravetto JR, exercised restricted stock units and subsequently sold a portion of the acquired common stock to cover tax liabilities.

Novanta Inc. has issued its proxy statement for the 2026 Annual Meeting of Shareholders, detailing director nominations, executive compensation advisory vote, and auditor appointment.

Novanta Inc. announces its annual shareholder meeting to be held virtually on May 29, 2025, to vote on director elections, executive compensation, and the appointment of an independent accounting firm.

Novanta Inc. will hold its annual shareholder meeting virtually on May 8, 2024, to vote on the election of directors, executive compensation, and the appointment of an independent accounting firm.

BlackRock, Inc. has disclosed beneficial ownership of 4,822,354 shares, representing 13.5% of the outstanding common stock of Novanta Inc., as of June 30, 2026.

Vanguard Capital Management reports beneficial ownership of 1,886,765 shares, representing 5.27% of Novanta Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 7.01% of Novanta Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership stake in Novanta Inc. following an internal realignment.

T. Rowe Price Associates, Inc. has filed an Amendment No. 2 to Schedule 13G, reporting a 2.7% beneficial ownership stake in Novanta Inc.

The Vanguard Group has increased its beneficial ownership in Novanta Inc. to 12.17% of common stock, holding 4,378,888 shares.